A. Michael Lincoff, MD

• Director, Center for Clinical Research and Vice Chairman for Clinical Research of the Cleveland Clinic Lerner Research Institute
• Director, Cleveland Clinic Coordinating Center for Clinical Research (C5Research)
• Vice Chairman, Department of Cardiovascular Medicine, Cleveland Clinic
• Charles and Charlotte Fowler Endowed Chair in Cardiovascular Research, Cleveland Clinic

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-09-30, Dr. Lincoff has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Lincoff receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Novo Nordisk, A/S
• Eli Lilly and Company
• TD Cowen
• Capricor Therapeutics, Inc.
• Johnson & Johnson

Fiduciary Role. Dr. Lincoff serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:

• Canary Cure

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.